Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen-specific TCR-T cells in solid tumors
NCT05194735Phase 2Terminated
- Sponsor
- Alaunos Therapeutics
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial in gynecologic cancer, colorectal cancer (CRC), pancreatic cancer (PC) and 2 more (2 arms), sponsored by Alaunos Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 1 year, Dose Limiting Toxicities at 28 days and 1 more. Started Apr 2022; status: terminated.
02
Conditions
gynecologic cancercolorectal cancer (CRC)pancreatic cancer (PC)non-small cell lung cancer (NSCLC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05194735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194735.